within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BA05_Ajmaline;

model Ajmaline
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 5.444444444444446e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.0015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0016,
    k12 = 5.527777777777777e-06,
    k21 = 5.527777777777777e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ajmaline</td></tr><tr><td>ATC code:</td><td>C01BA05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>19.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ajmaline is a class Ia antiarrhythmic agent used primarily for the diagnosis of Brugada syndrome and the management of supraventricular and ventricular arrhythmias. It is administered intravenously for acute arrhythmic events, and orally for long-term therapy in some countries. Ajmaline is not available in the United States but is used in several European and Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01BA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ajmaline;
